title: Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients.
abstract: It is well established that the involvement of reactive species in the pathophysiology of several neurological diseases, including phenylketonuria (PKU), a metabolic genetic disorder biochemically characterized by elevated levels of phenylalanine (Phe). In previous studies, we verified that PKU patients (treated with a protein-restricted diet supplemented with a special formula not containing L-carnitine and selenium) presented high lipid and protein oxidative damage as well as a reduction of antioxidants when compared to the healthy individuals. Our goal in the present study was to evaluate the effect of Phe-restricted diet supplemented with L-carnitine and selenium, two well-known antioxidant compounds, on oxidative damage in PKU patients. We investigated various oxidative stress parameters in blood of 18 treated PKU patients before and after 6 months of supplementation with a special formula containing L-carnitine and selenium. It was verified that treatment with L-carnitine and selenium was capable of reverting the lipid peroxidation, measured by thiobarbituric acid-reactive species, and the protein oxidative damage, measured by sulfhydryl oxidation, to the levels of controls. Additionally, the reduced activity of glutathione peroxidase was normalized by the antioxidant supplementation. It was also verified a significant inverse correlation between lipid peroxidation and L-carnitine blood levels as well as a significant positive correlation between glutathione peroxidase activity and blood selenium concentration. In conclusion, our results suggest that supplementation of L-carnitine and selenium is important for PKU patients since it could help to correct the oxidative stress process which possibly contributes, at least in part, to the neurological symptoms found in phenylketonuric patients.
authors.affiliation: Serviço de Genética Médica, HCPA, UFRGS, Rua Ramiro Barcelos, Porto Alegre, RS, Brazil. angelasitta@yahoo.com.br
authors.forename: A
authors.initials: A
authors.lastname: Sitta
authors.forename: C S
authors.initials: CS
authors.lastname: Vanzin
authors.forename: G B
authors.initials: GB
authors.lastname: Biancini
authors.forename: V
authors.initials: V
authors.lastname: Manfredini
authors.forename: A B
authors.initials: AB
authors.lastname: de Oliveira
authors.forename: C A Y
authors.initials: CA
authors.lastname: Wayhs
authors.forename: G O S
authors.initials: GO
authors.lastname: Ribas
authors.forename: L
authors.initials: L
authors.lastname: Giugliani
authors.forename: I V D
authors.initials: IV
authors.lastname: Schwartz
authors.forename: D
authors.initials: D
authors.lastname: Bohrer
authors.forename: S C
authors.initials: SC
authors.lastname: Garcia
authors.forename: M
authors.initials: M
authors.lastname: Wajner
authors.forename: C R
authors.initials: CR
authors.lastname: Vargas
mesh_terms: D000293:Adolescent; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002331:Carnitine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019587:Dietary Supplements; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects*; D010661:Phenylketonurias / Q000097:blood / Q000178:diet therapy / Q000503:physiopathology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012643:Selenium / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D055815:Young Adult
chemical_list: D000975:Antioxidants; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D012643:Selenium; D002331:Carnitine